Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL

Akbayir, Serin; Muşlu, Necati; Erden, Sema; Bozlu, Murat

doi:10.5152/tud.2016.52463

Cited by 10 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LncRNA HCG11, lncRNA LINC01138, and SUZ12P1 were considered to play important roles in regulating PCa carcinogenesis through promoting proliferation and inhibiting apoptosis of PC cells [ 6 , 7 ]. In addition, many biomarkers including miRNAs have been investigated as diagnostic value in prostate cancer [ 8 – 10 ]. However, few reports have described the role of circular RNAs (circRNAs) in PCa.…”

Section: Introductionmentioning

confidence: 99%

Circular RNA Myosin Light Chain Kinase (MYLK) Promotes Prostate Cancer Progression through Modulating Mir-29a Expression

Dai

Xiong

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

BackgroundIn developed countries, prostate cancer (PCa) is a frequently diagnosed cancer with the second highest fatality rate. Circular RNAs (circRNAs) are a class of endogenous non-coding RNAs (ncRNAs) stably expressed in cells and involved in a series of carcinomas. However, few research studies have reported on the role of circRNAs in PCa.Material/MethodsWe used qRT-PCR to detect the expression of circMYLK (circRNA ID: hsa_circ_0141940) and miR-29a in PCa tissues and cell lines. MTT, colony formation, and TUNEL assays were performed to analysis the cell viability of PCa cells. Transwell and wound scratch assays were performed to investigate the cell invasion and migration of PCa cells.ResultsIn the present study, we confirmed that circMYLK expression level was significantly higher in PCa samples and PCa cells than in normal tissues and normal prostatic cells. The upregulated circRNA-MYLK promoted PCa cells proliferation, invasion, and migration; however, si-circRNA-MYLK significantly accelerated the PCa cell apoptosis. We also observed that the aforementioned function of circRNA-MYLK on PCa cells was affected through targeting miR-29a.ConclusionsWe confirmed circRNA-MYLK was an oncogene in PCa and revealed a novel mechanism underlying circRNA-MYLK in PC progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Circular RNA Myosin Light Chain Kinase (MYLK) Promotes Prostate Cancer Progression through Modulating Mir-29a Expression

Dai

Xiong

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…It is one of the slow-progressing and silent cancers seen in advanced ages and started to be diagnosed at an earlier age due to increasing screening studies in recent years. Despite progress, PCa remains a major medical problem for affected men, so research into the risk factors, early diagnosis and treatment of the disease is ongoing [2] [3] . Well-known risk factors for PCa are a history of PCa in the family, age, and race.…”

Section: Introductionmentioning

confidence: 99%

“…Well-known risk factors for PCa are a history of PCa in the family, age, and race. Although its aetiology is not clear, it is known to occur at different frequencies between ethnic populations and countries [2] [4] . Additionally, differences in PCa cases and outcomes have been observed among men of different racial groups.…”

Section: Introductionmentioning

confidence: 99%

Investigation of the relationship between endothelial nitric oxide synthase T786C polymorphism and PSA, PSA derivatives, and prostate cancer in the Turkish population

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: Prostate cancer is a slowly progressing cancer seen in older men. Despite advances, prostate cancer remains a major medical problem for affected men. Risk factors of prostate cancer include age, race and prostate cancer family history. Prostate cancer may occur at different frequencies between ethnic populations and countries. Currently, studies on genetic risk factors in prostate cancer etiology have been increasing, and the results show that they are interrelated. Nitric oxide synthase is the enzyme that converts L-arginine to Nitric Oxide. It has been shown that changes in endothelial nitric oxide synthase have an important role in carcinogenesis and the cardiovascular system. There are studies evaluating the relationship of endothelial nitric oxide synthase gene T786C polymorphism with prostate cancer risk in different populations and the results are contradictory. Based on this, we aimed to reveal whether endothelial nitric oxide synthase T786C polymorphism exists in the participants and whether it was associated with prostate cancer. Methods: Archival samples included in this study were whole blood samples taken from patients who were grouped according to prostate biopsy pathology results and from healty participants. DNA was isolated from these whole blood samples, and real-time polymerase chain reaction analysis was performed for endothelial nitric oxide synthase T786C polymorphism with LightCycler 480 II. Measured free and total prostate specific antigen serum levels were evaluated retrospectively. Results: There was a statistically difference between patient-healthy control and control-healthy control groups in terms of genotype distributions for endothelial nitric oxide synthase T786C polymorphism. Healthy controls were more likely to have TC and CC genotypes, and C allele than the other two groups. Conclusions: Contrary to the previous studies, in this study, no risk relationship was found between endothelial nitric oxide synthase T786C polymorphism and prostate cancer in the Turkish population.

show abstract

“…The main diagnostic criteria in PC are digital rectal examination (DRE), serum prostatespecific antigen (PSA) level, and transrectal ultrasound-guided biopsy, respectively. The PSA is exclusively expressed in prostate tissue yet it is not specific for diagnosis [3]. The increased levels may be associated with numerous clinical conditions such as benign prostate hyperplasia (BPH), prostatitis, other infections, trauma, and urinary retention.…”

Section: Introductionmentioning

confidence: 99%

Investigating differential miRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis

Hasanoğlu¹,

Göncü²,

Yücesan³

et al. 2021

Turk J Med Sci

View full text Add to dashboard Cite

Background/ Aim: MicroRNAs (miRNAs) are known up-to-date candidate biomarkers for several diseases. In addition obtaining miRNA from different body fluids such as serum, plasma, saliva, and urine is relatively easy to handle. Herein we aimed to detect miRNAs as biomarkers for early stage prostate cancer (PC). For this purpose, we used urine and serum samples to detect any significant differences in miRNA profiles between patients and healthy controls. Materials and Methods: Total ribonucleic acid (RNA) in urine and serum samples were isolated from eight untreated PC patients and thirty healthy individuals were screened for miRNA profile and candidate miRNAs were validated. Whole urinary and serum miRNA profile was analyzed using Affymetrix GeneChip miRNA 4.0 Arrays. Candidate miRNAs were investigated by stem-loop reverse transcription-polymerase chain reaction. Results: According to our results, when analyzed urinary samples of PC patients 49 miRNAs were detected up-regulated and 14 miRNAs were found down-regulated when compared with healthy controls. According to the serum samples 19 miRNAs were found up-regulated and 21 miRNAs were found down-regulated when compared with healthy individuals as well. Interestingly we detected overlapped only four miRNAs (MIR320A, MIR4535, MIR4706, MIR6750) that commonly increase or decrease in both serum and urine samples. Among them MIR320A was found down-regulated, and MIR4535, MIR4706, MIR6750 were found up-regulated fo urine samples. However only MIR6750 was up-regulated and the other three miRNAs were down-regulated for serum samples. 2 Conclusion: Notably, the expression profile of MIR320A was significantly altered in urine specimens of prostate cancer patients. We considered that MIR320A has been evaluated as a valuable biomarker that can be used in the early diagnosis of the PC.

show abstract

Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL

Cited by 10 publications

References 39 publications

Circular RNA Myosin Light Chain Kinase (MYLK) Promotes Prostate Cancer Progression through Modulating Mir-29a Expression

Circular RNA Myosin Light Chain Kinase (MYLK) Promotes Prostate Cancer Progression through Modulating Mir-29a Expression

Investigation of the relationship between endothelial nitric oxide synthase T786C polymorphism and PSA, PSA derivatives, and prostate cancer in the Turkish population

Investigating differential miRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis

Contact Info

Product

Resources

About